IMMU Immunicum AB

Immunicum Announces Investor Event and Conference Participation for April

Immunicum Announces Investor Event and Conference Participation for April

Press Release

7 April 2021

Immunicum Announces Investor Event and Conference Participation for April

Immunicum AB (publ) today announced its participation in multiple upcoming investor conferences in April and that it will host a virtual Investor Event on Thursday, April 22, 2021. The event will feature presentations by Immunicum’s management team to provide an overview of the Company’s strategy and outlook for its two Phase II clinical candidates, immune primer ilixadencel and cancer relapse vaccine DCP-001.

The agenda and further details on accessing the live webcast of the event will be made available on the Company’s website, , in “”, prior to the event. Questions can be sent before and during the event to . The recording will also be available following the conclusion of the event.

Details on the investor event include:

Event:              Immunicum April Investor Event

Date:               April 22, 2021

Time:              13:00 CET / 7:00 am EDT

In addition, Immunicum announced its participation in the following upcoming virtual investor conferences in April:

  • Solebury Trout European Biotech Investor Days 2021, April 7 – 8, 2021

     
    • Erik Manting, Chief Executive Officer, will attend and present at the conference.

       
  • Kempen & Co Life Sciences Virtual Conference – European Cell, Gene & RNA based companies, April 28, 2021

     
    • Erik Manting, Chief Executive Officer, will attend and present at the conference.

As of today, an updated corporate presentation is available on the of Immunicum’s corporate website.

For more information, please contact:

Erik Manting

Chief Executive Officer

Telephone:

E-mail:

Investor Relations

Sijme Zeilemaker

Head of Investor Relations & Corporate Communication

Telephone:

E-mail: 

Media Relations

Eva Mulder and Sophia Hergenhan

Trophic Communications

Telephone: 56

E-mail: 

About Immunicum AB (publ)

Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm.

Attachment



EN
07/04/2021

Underlying

IMMUImmunicum AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunicum AB

Free Trial
IMMU IMMUNICUM AB

Mendus AB: 1 director

A director at Mendus AB bought 55,000 shares at 5.000SEK and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

12/17/25 December 17, 2025 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Collaboration unveils path forward for ilixadencel

Mendus has announced a collaboration with Institut Bergonié, an established comprehensive cancer centre in France, to test ilixadencel in soft tissue sarcomas (STS) as part of an ongoing Phase I/II basket trial (REGOMUNE). The trial is a multi-centre, prospective open-label study assessing the combination of regorafenib (a tyrosine kinase inhibitor) and avelumab (an immune checkpoint inhibitor) in various solid tumours. Ilixadencel will be evaluated along with a combination in one of the treatme...

07/24/24 July 24, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Recent clinical data highlight vididencel’s potential

Mendus recently presented positive data from two ongoing clinical studies, ADVANCE II and ALISON, at the EHA and ESMO conferences, respectively. While the Phase I ALISON trial, evaluating lead asset vididencel in ovarian cancer, met its primary endpoint of generating sufficient vaccine-induced responses (VIR), further analysis of ADVANCE II data (studying vididencel as a maintenance therapy in AML) confirmed the drug’s potential in generating a broader immune response through both T-cell and B-c...

06/21/24 June 21, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - All hands on deck as inflection points approach

With Mendus’s Q124 results, management recapped its clinical priorities, which are all progressing as expected. The focus remains on the AMLM22-CADENCE trial for lead cancer vaccine vididencel, in combination with oral azacitidine as a maintenance treatment for acute myeloid leukaemia (AML). R&D expenses came in slightly ahead of expectations with the ramp up in clinical activity, including preparation for the subsequent pivotal Phase III trial, with large-scale manufacturing of vididencel (plan...

05/20/24 May 20, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Gross proceeds of c SEK69m to advance pipeline

Mendus has reported gross proceeds of c SEK69.1m from the exercise of series TO3 warrants that were issued in connection with the July 2023 raise of SEK317m. Management anticipates that these proceeds will extend the cash runway to Q325 and will be applied to progress its clinical pipeline, mainly in preparation for a registrational trial for lead cancer vaccine vididencel, targeting acute myeloid leukaemia (AML) in the maintenance setting. Management expects the registrational study to commence...

04/04/24 April 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch